Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00355589
First received: July 20, 2006
Last updated: October 8, 2012
Last verified: October 2012
  Purpose

The purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.


Condition Intervention Phase
Hypertension
Blood Pressure, High
Drug: Ramipril and hydrochlorothiazide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Efficacy and Safety of a Combination of Ramipril Plus Hydrochlorothiazide Versus the Component Monotherapies in Subjects With Essential Hypertension

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Compare the effects on sitting diastolic blood pressure of two antihypertensive drugs in combination against each antihypertensive alone after an eight week treatment period.

Secondary Outcome Measures:
  • Compare the effect on sitting diastolic blood pressure of two antihypertensive drugs in combination taken once daily against one antihypertensive drug taken twice daily.
  • Compare the effect on sitting diastolic blood pressure of a dose of an antihypertensive drug taken once daily against half of the same dose taken twice daily.
  • Compare the effect on the sitting and standing blood pressure among all treatment groups.
  • Compare the safety of each medication regimen stated above.
  • Compare the effect on mean 24-hour diastolic blood pressure (ABPM) of the medication regimens stated above.

Study Start Date: July 2006
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previously diagnosed, or newly diagnosed essential hypertension. Blood pressure must be within a minimum and maximum range prior to drug treatment.

Exclusion Criteria:

  • Inability to discontinue all prior antihypertensive medications
  • Heart failure
  • History of stroke, myocardial infarction, or chest pain within 3 years, or an abnormal heart rhythm
  • Liver or kidney disease
  • Certain drugs used to treat other conditions like an enlarged prostate gland, or arthritis
  • Allergy or reactions to certain medications used to treat high blood pressure

Other protocol-defined inclusion and exclusion criteria apply.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00355589

  Hide Study Locations
Locations
United States, Alabama
Cahaba Research Inc.
Birmingham, Alabama, United States, 35242
Clinical Research Associates
Huntsville, Alabama, United States, 35801
United States, Arizona
Pulmonary Associates
Glendale, Arizona, United States, 85306
United States, California
Impact Clinical Trials
Beverly Hills, California, United States, 90211
Lovelace Scientific Resources, Inc.
Beverly Hills, California, United States, 90211
Associated Pharmaceutical Research Center, Inc.
Buena Park, California, United States, 90620
Marin Endocrine Care and Research
Greenbrae, California, United States, 94904
Memorial Research Medical Clinic
Long Beach, California, United States, 90806
The Intermed Group; Samaritan Medical Tower
Los Angeles, California, United States, 90017
National Research Institute
Los Angeles, California, United States, 90057
Clinical Trials Research
Roseville, California, United States, 95661
Bayview Research Group
Studio City, California, United States, 91604
Viking Clinical Research
Temecula, California, United States, 92591
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
United States, Florida
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States, 33765
Clinical Research of South Florida
Coral Gables, Florida, United States, 33134
University Clinical Research Deland, Inc.
Deland, Florida, United States, 32720
South Florida Clinical Research Center
Hollywood, Florida, United States, 33023
Innovative Research of West Florida
Largo, Florida, United States, 33770
International Research Associates, LLC
Miami, Florida, United States, 33156
Lifespan Research Foundation
Miami, Florida, United States, 33186
Sun Coast Clinical Research
New Port Richey, Florida, United States, 34652
Renstar Medical Research
Ocala, Florida, United States, 34471
Suncoast Clinical Research, Inc.
Palm Harbor, Florida, United States, 34684
University Clinical Research, Inc.
Pembroke Pines, Florida, United States, 33024
Lovelace Scientific Resources
Sarasota, Florida, United States, 34233
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States, 33401
United States, Georgia
Executive Health and Research Associates, Inc.
Atlanta, Georgia, United States, 30342
United States, Illinois
James R. Herron, MD, Ltd.
Chicago, Illinois, United States, 60610
Cedar Crosse Research Center
Chicago, Illinois, United States, 60607
Clinical Investigation Specialists, Inc.
Gurnee, Illinois, United States, 60031
United States, Indiana
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States, 46260
United States, Michigan
Michigan Institute of Medicine
Livonia, Michigan, United States, 48152
Medical Research Associates
Traverse City, Michigan, United States, 49684
United States, Minnesota
Twin Cities Clinical Research
Brooklyn Center, Minnesota, United States, 55430
United States, Nevada
Advanced Biomedical Research of America
Las Vegas, Nevada, United States, 89123
United States, New Jersey
Partners in Primary Care
Voorhees, New Jersey, United States, 08043
United States, North Carolina
Cumberland Research Assocites, LLC
Fayetteville, North Carolina, United States, 28304
Unifour Medical Research Associates
Hickory, North Carolina, United States, 28601
Triangle Medical Research Associates
Raleigh, North Carolina, United States, 27609
The Lipid Center
Statesville, North Carolina, United States, 28677
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States, 27103
Lyndhurst Gynecologic Associates, PA
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Sterling Research Group, Inc.
Cincinnati, Ohio, United States, 45219
Smith Clinical Research
Marion, Ohio, United States, 43302
Radiant Research - Mogadore
Mogadore, Ohio, United States, 44260
United States, Oklahoma
Lion Research
Norman, Oklahoma, United States, 73069
United States, Oregon
Medford Medical Clinic Research Dept.
Medford, Oregon, United States, 97504
United States, Pennsylvania
Philadelphia Health Associates
Philadelphia, Pennsylvania, United States, 19146
United States, South Carolina
Medical Research South
Charleston, South Carolina, United States, 29407
SC Clinical Research Center, LLC
Columbia, South Carolina, United States, 29201
Radiant Research - Greer
Greer, South Carolina, United States, 29651
United States, Texas
MetaClin Research, Inc.
Austin, Texas, United States, 78704
Punzi Medical Center
Carrollton, Texas, United States, 75006
Research Across America
Dallas, Texas, United States, 75234
Radiant Research - San Antonio
San Antonio, Texas, United States, 78229
WellMed Medical Management
San Antonio, Texas, United States, 78229
United States, Virginia
Clinical Research Associates of Tidewater
Norfolk, Virginia, United States, 23507
The Chase Wellness Center, Inc
Virginia Beach, Virginia, United States, 23455
United States, Washington
Radiant Research - Tacoma
Lakewood, Washington, United States, 98499
Sponsors and Collaborators
Pfizer
  More Information

No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00355589     History of Changes
Other Study ID Numbers: K749-06-3001, B5051001
Study First Received: July 20, 2006
Last Updated: October 8, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Hypertension
High Blood Pressure
Diuretic
Angiotensin converting enzyme inhibitor
Ambulatory blood pressure monitoring

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Ramipril
Hydrochlorothiazide
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013